K2 Principal Fund L.P. purchased a new stake in shares of Alere Inc. (NYSE:ALR) in the second quarter, according to its most recent filing with the SEC. The firm purchased 10,516 shares of the medical research company’s stock, valued at approximately $528,000.

Several other hedge funds also recently bought and sold shares of the company. Teacher Retirement System of Texas increased its stake in shares of Alere by 0.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,958 shares of the medical research company’s stock worth $349,000 after purchasing an additional 28 shares in the last quarter. Asset Management One Co. Ltd. increased its stake in shares of Alere by 0.5% during the 1st quarter. Asset Management One Co. Ltd. now owns 15,940 shares of the medical research company’s stock worth $633,000 after purchasing an additional 79 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in shares of Alere by 0.6% during the 1st quarter. Public Employees Retirement System of Ohio now owns 40,617 shares of the medical research company’s stock worth $1,614,000 after purchasing an additional 258 shares in the last quarter. Prudential Financial Inc. increased its stake in shares of Alere by 5.8% during the 2nd quarter. Prudential Financial Inc. now owns 5,515 shares of the medical research company’s stock worth $277,000 after purchasing an additional 300 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of Alere by 3.0% during the 1st quarter. Pacer Advisors Inc. now owns 10,810 shares of the medical research company’s stock worth $429,000 after purchasing an additional 319 shares in the last quarter. Institutional investors own 88.76% of the company’s stock.

A number of brokerages have recently weighed in on ALR. BidaskClub cut shares of Alere from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Canaccord Genuity reissued a “hold” rating and set a $51.00 price objective on shares of Alere in a research note on Tuesday. Zacks Investment Research cut shares of Alere from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $51.00 price objective on shares of Alere in a research note on Thursday, June 1st. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. Alere presently has a consensus rating of “Hold” and a consensus target price of $48.00.

Alere Inc. (NYSE ALR) opened at 50.35 on Friday. The stock’s market capitalization is $4.41 billion. The stock’s 50 day moving average is $49.61 and its 200-day moving average is $47.44. Alere Inc. has a 52 week low of $34.41 and a 52 week high of $50.63.

ILLEGAL ACTIVITY WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/23/k2-principal-fund-l-p-takes-528000-position-in-alere-inc-alr.html.

Alere Profile

Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.

Want to see what other hedge funds are holding ALR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alere Inc. (NYSE:ALR).

Institutional Ownership by Quarter for Alere (NYSE:ALR)

Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with MarketBeat.com's FREE daily email newsletter.